Prostatype Genomics AB announces outcome of rights issue of units
The subscription period in Prostatype Genomics AB’s (”Prostatype Genomics” or the “Company”) rights issue, in which the public was also given the opportunity to participate, ended on 20 July 2022. The rights issue was subscribed (including pre-subscription commitments) to a total of approximately 79.5 percent, meaning that a guarantee commitment of approximately 20.5 percent has been activated to reach a total subscription of 100 percent. Prostatype Genomics will thus be provided proceeds of approximately SEK 22.5 million before deduction of transaction related costs. Settlement notes are expected to be sent out today, 22 July 2022.
Subscription, allocation, and payment
The rights issue was subscribed for a total of approximately SEK 17.9 million, including pre-subscription commitments of approximately SEK 8.5 million, corresponding to a subscription ratio of 79.5 percent. In addition, guarantee commitments corresponding to approximately SEK 4.6 million have been activated, meaning that Prostatype Genomics is provided 100 percent of the issue volume. Prostatype Genomics will thus initially receive approximately SEK 22.5 million before deduction of transaction related costs of approximately SEK 3.1 million in total (including compensation to guarantors of approximately SEK 1.4 million). Through the rights issue, 7,755,895 shares and 7,755,895 warrants of series TO 2 are issued. A total of 306,315 units (corresponding to approximately SEK 16.9 million) were subscribed for with the support of unit rights, including subscription commitments of approximately SEK 8.5 million. The allocation of units has been made in accordance with the allocation principles described in the prospectus that was published by the Company on the 28 June 2022. Subscribers who are allotted units without pre-emptive rights will receive settlement notes, which are scheduled to be sent out today, 22 July 2022. Allotted units without pre-emptive rights shall be paid in accordance with the instructions on the settlement note.
Number of shares and share capital
When the initial part of the rights issue has been registered with the Swedish Companies Registration Office, the total number of shares in Prostatype Genomics will have increased by 7,755,895 shares, from 15,103,602 shares to 22,859,497 shares. The Company’s share capital will, upon registration, have increased by SEK 465,353.70, from SEK 906,216.12 to SEK 1,371,569.82. For the shareholders who have not participated in the rights issue, a dilution of approximately 34 percent will be recognized. In addition, there will be a total of 7,755,895 outstanding warrants of series TO 2.
Trading in paid subscribed unit (BTU)
Trading in BTU’s will take place on Nasdaq First North Growth Market until the rights issue is registered with the Swedish Companies Registration Office. The registration is expected to take place around 9 August 2022.
Summary terms for warrants of series TO 2
The newly issued warrants of series TO 2 (ISIN code SE0018220014) are planned to be traded on Nasdaq First North Growth Market as soon as possible after the Swedish Companies Registration Office has registered the rights issue. Each warrant of series TO 2 entitles the holder to subscribe for one (1) new share in Prostatype Genomics during the period from 9 March 2023 until and including 30 March 2023. The exercise price will be the same price per share as the subscription price in the initial part of the rights issue, i.e. SEK 2.90. If the warrants of series TO 2 are fully exercised, the Company can be provided an additional maximum of approximately SEK 22.5 million before deduction of transaction related costs. Complete terms and conditions for warrants of series TO 2 are available on the Company's website (www.prostatypegenomics.com).
Advisors
In connection with the rights issue, Prostatype Genomics has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB has assisted the Company with advice regarding communication.
For further information about the rights issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-07-2022 14:20 CET.
Press contact
nicklas.rosendal@prostatypegenomics.com
Certified Advisor
Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.